SCMOM 2012_ViaCyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01), with subcutaneous implantation in a retrievable and immune-isolating encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin in a regulated manner to control blood glucose levels. ViaCyte #39;s goal is a product that can free Type 1 and 2 diabetic patients from long-term insulin dependence. ViaCyte has received substantial financial support from both CIRM and JDRF. http://www.viacyte.com Presenter: Paul Laikind, President and CEO, ViaCyteFrom:AllianceRegenMedViews:5 1ratingsTime:16:42More inScience Technology

Go here to read the rest:
SCMOM 2012_ViaCyte - Video

Recommendation and review posted by G. Smith

SCMOM 2012_MaxCyte
MaxCyte is the leader in scalable and clinical cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of diseases. MaxCyte #39;s customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed, well validated and has received MF designation with CBER at US FDA. http://www.maxcyte.com Presenter: Douglas Doerfler, President and CEO, MaxCyteFrom:AllianceRegenMedViews:2 1ratingsTime:13:14More inScience Technology

Original post:
SCMOM 2012_MaxCyte - Video

Recommendation and review posted by G. Smith

SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology

Read more here:
SCMOM 2012_Stanford Cardiovascular Institute - Video

Recommendation and review posted by G. Smith

SCMOM 2012_Ensuring Maximum Reimbursement for a Regen Med Product
How to ensure that your regenerative medicine product is appropriately reimbursed is an increasingly difficult task for company executives. Thriving in both the private insurance and Medicare markets requires careful and long-range planning. Using a case-study approach, these panelists will discuss reimbursement challenges, goals, and strategies. They will discuss how to get products covered and reimbursed by payers in an environment that demands cost effectiveness and value.From:AllianceRegenMedViews:7 0ratingsTime:58:34More inScience Technology

See the original post:
SCMOM 2012_Ensuring Maximum Reimbursement for a Regen Med Product - Video

Recommendation and review posted by G. Smith

SCMOM 2012_The Regen Med Investment Hypothesis
This session will examine the regenerative medicine investment hypothesis from the perspective of the primary sources of capital at key stages in the development process from discovery to late-stage clinical development. Additionally, panelists will discuss different parts of the sector -- therapeutics, devices, tools, and services - and different types of business models to explore how they evaluate risk and why some models are more compelling than others. Investor perspectives represented on the panel will include traditional venture, angels, institutional investors and corporate strategics.From:AllianceRegenMedViews:3 0ratingsTime:56:18More inScience Technology

Read the original here:
SCMOM 2012_The Regen Med Investment Hypothesis - Video

Recommendation and review posted by G. Smith

Stem Cells for Regenerative Medicine
http://www.ucsf.edu Stem cell banks might one day be used to meet the tissue-transplant needs of most of the population. Just as there are universal blood donors, cells from universal donors could be used to develop induced pluripotent stem cells (iPS cells) or adult stem cells for use in repairing the nervous system, the heart or other organs. Off-the-shelf cell lines could be made available for recipients in a timely way, with matching likely to lower risk of transplant rejection. UCSF stem cell scientist Bruce Conklin, MD, discusses.From:UCSFPublicAffairsViews:20 1ratingsTime:03:29More inEducation

Read the original here:
Stem Cells for Regenerative Medicine - Video

Recommendation and review posted by G. Smith